Entheon Biomedical Corp. Announces DTC Eligibility
Vancouver, British Columbia-(August 24, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction is pleased to announce that […]